Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Ascendis Pharma (ASND) and Avalo Therapeutics (AVTX)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cytokinetics (CYTK – Research Report), Ascendis Pharma (ASND – Research Report) and Avalo Therapeutics (AVTX – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cytokinetics (CYTK)
In a report released today, Leonid Timashev from RBC Capital maintained a Buy rating on Cytokinetics, with a price target of $101.00. The company’s shares closed last Wednesday at $62.27.
According to TipRanks.com, Timashev is a 5-star analyst with an average return of
Cytokinetics has an analyst consensus of Strong Buy, with a price target consensus of $95.83, a 57.3% upside from current levels. In a report issued on February 19, Barclays also maintained a Buy rating on the stock with a $87.00 price target.
See today’s best-performing stocks on TipRanks >>
Ascendis Pharma (ASND)
Cantor Fitzgerald analyst Li Watsek maintained a Buy rating on Ascendis Pharma yesterday and set a price target of $300.00. The company’s shares closed last Wednesday at $241.38.
According to TipRanks.com, Watsek is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Ascendis Pharma is a Strong Buy with an average price target of $293.33, implying a 23.3% upside from current levels. In a report released yesterday, TipRanks – Google also upgraded the stock to Buy with a $266.00 price target.
Avalo Therapeutics (AVTX)
In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Avalo Therapeutics, with a price target of $48.00. The company’s shares closed last Wednesday at $18.36.
According to TipRanks.com, Rahimi is a 5-star analyst with an average return of
Currently, the analyst consensus on Avalo Therapeutics is a Strong Buy with an average price target of $40.40.
